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Estrogen plays an important role in maintaining bone density in women. Estrogen receptor (ER) is
expressed in osteoblasts and osteoclasts; however, the precise mechanism of ER in bone is not fully
understood. In the present study, we generated a conditional transgenic mouse caERaColI that
expresses the constitutively active ERa in osteoblasts using collagen type I promoter-driven Cre
transgenic mice. The caERaColI mice showed increased bone mineral density (BMD). Osteoblasts
prepared from caERaColI mice expressed high levels of osteoprotegerin and decreased levels of
IL-6, both of which are known to regulate osteoclast differentiation. These results suggest that
ERa regulates osteoprotegerin and IL-6 production in osteoblasts and modulates BMD. The condi-
tional transgenic mouse model is useful for understanding the in vivo function of ERa.
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Estrogen, a sex steroid hormone regulates bone metabolism
that is controlled by a balance between bone resorption by osteo-
clasts and bone formation by osteoblasts [1]. Estrogen is beneﬁcial
for bone health. The physiological function of estrogen is mediated
by the estrogen receptors (ER)a and ERb [2]. ERs are transcription
factors that regulate the expression of estrogen-targeted genes in
response to hormone binding. ERs are expressed on both osteo-
blasts [3,4] and osteoclasts [5].
The mechanisms by which estrogen increases bone mass and its
deﬁciency leads to bone loss are not fully understood. Estrogen
deﬁciency increases the expression of receptor activator of nuclear
factor j B ligand (RANKL) [6]. RANKL is expressed on the surface of
osteoblasts. Binding of RANKL to its receptor RANK on pre-osteo-
clasts is necessary for the differentiation and proliferation of pre-
osteoclasts into mature osteoclasts [7]. RANKL is neutralized bychemical Societies. Published by E
me; MAR, mineral apposition
, osteoclast surface per bone
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ue).its soluble decoy receptor osteoprotegerin (OPG), which is
produced and secreted by osteoblasts [8]. It has been suggested
that estrogen suppresses RANKL production [9] and increases
OPG production [10] by osteoblastic cells. Therefore, estrogen deﬁ-
ciency induces an increase in the RANKL/OPG ratio and leads to an
imbalance in bone resorption over bone formation [11,12]. Estro-
gen treatment has been shown to inhibit osteoclast formation from
mononuclear hematopoietic stem cells [13,14]. In addition, several
lines of evidence indicate that estrogen directly stimulates osteo-
genic activity and protects against osteoblastic apoptosis [15,16].
These results imply that ER has a crucial role in osteoblasts; how-
ever, its in vivo function is poorly understood.
To examine the role of ERa in a mouse model, we utilized a con-
stitutively active ERa (caERa) mutant that had a substitution of
tyrosine to serine at 537 (ERa Y537S) [17]. It is known that even
in the absence of ligand stimulation, the ERa Y537S exhibits high
transcription activity. Thus, we assumed that the ERa Y537S is use-
ful for analyzing the gain-of-function of ERa in vivo. We generated
conditional transgenic mice that express the caERa in osteoblasts
by using ColI-Cre mice [18]. These mice displayed increased bone
mineral density (BMD). In addition, primary osteoblasts prepared
from caERaColI mice expressed higher levels of OPG and lower
levels of IL-6 compared to those from wild-type (WT) mice. This
mouse model shows a crucial role of ERa in the bone and aids in
our understanding of in vivo function of ERa.lsevier B.V. All rights reserved.
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2.1. Construction of constitutive active ERa and luciferase assay
The Flag-tagged pcDNA3 (Invitrogen, San Diego, CA) construct
pcDNA3-Flag-ERawas prepared by insertion of open reading frame
of humanERa into pcDNA3containing Flag tag. Constitutively active
ERa (caERa) containing Y537S substitution was generated by
site-directed mutagenesis using pcDNA3-Flag-ERa according to
the previous report [17]. HeLa cells at a density of 1  104 cells/well
on 24-well plates were transfected with a ﬁreﬂy luciferase reporter
gene ERE-tk-Luc (0.8 lg), a control Renilla luciferase reporter gene
pRL-CMV (0.7 lg) (Promega, Madison, WI), 5 ng of expression vec-
tors for caERa or ERa in phenol red-free DMEM containing 10% dex-
tran-coated charcoal-treated FCS (dccFCS) using Lipofectamine
2000 transfection reagent (Invitrogen). Twelve hours after transfec-
tion, cells were treated with or without 10 nM 17b-estradiol (E2) or
1 lM ICI182,780 (ICI) for 24 h and luciferase assay was performed.
Data were represented as the mean ± S.D. of three independent
experiments.
2.2. Construction of the transgene
A CAG-GFPﬂoxed-caERa transgene plasmidwas constructed using
a pCALwL vectorwhich contains a CAG promoter, being a composite
promoter consisting of a cytomegalovirus IE enhancer, a chicken b-
actin promoter, two functional loxP sites, and a rabbit b-globin pol-
yadenylation signal [19]. cDNAs for GFP fused to Histone H2B [20]
and caERa were subcloned into sites between the two loxP sites
and upstream of the polyadenylation signal, respectively.
2.3. Generation of transgenic mice
The plasmid CAG-GFPﬂoxed-caERa was linearlized with restric-
tion enzyme digestion. Transgenic mice were produced bymicroin-
jecting the linearlized plasmid into the pronuclei of fertilized eggs
from C57BL/6 mice as described previously [21]. Transgenic mice
were identiﬁed by PCR assays of genomic DNA extracted from the
tail, and transgene expression was monitored by GFP ﬂuorescence
using a stereomicroscope. Primers derived from the 50- and 30-ﬂank-
ing sequences of GFP (50-ACGTGCTGGTTGTTGTGCTGTCTCTCATCA-
30 and50-TGATTTGATCCCCGGGTACCGAGCGAC-30)wereused to am-
plify a 1.9 kb product. ColI-Cre mice were kindly provided by Dr. G.
Karsenty [18], and ROSA26LacZ reporter mice were obtained from
The Jackson Laboratory (Bar Harbor, ME). For Cre transgenic mice,
primers derived from Cre (50-CCTGGAAAATGCTTCTGTCCGTTTGCC-
30 and 50-GAGTTGATAGCTGGCTGGTGGCAGATG-30) were used to
amplify a 653-bp product. For ROSA26LacZ transgenic mice, prim-
ers; 50-GCGAAGAGTTTGTCCTCAACC-30, 50-AAAGTCGCTCTGA
GTTGTTAT-30 and 50-GGAGCGGGAGAAATGGATATG-30 were used
to amplify a 340-bp product for the transgene and a 650-bp product
for wild-type allele (The Jackson Laboratory). CAG-GFPﬂoxed-caERa
transgenicmicewerematedwith ColI-Cre transgenicmice to obtain
the conditional transgenic mice caERaColI. ColI-Cre/ROSA26LacZ re-
porter mice were generated by a cross-breeding of ROSA26LacZ and
ColI-Cre mice and used to track the activity of the ColI promoter
throughout the ontogenyof themouse. All animal experimentswere
approved by the Institutional Animal Care and Use Committee.
2.4. LacZ staining
Assessment of b-galactosidase (b-gal) activity was performed
according to the method of Nagy et al. with a slight modiﬁcation
[21]. Embryos (10 dpc) and frozen sections (10 lm thick) of spine
from neonatal ColI-Cre/ROSA26LacZ mice (P1) were ﬁxed with a
0.25% glutaraldehyde solution for 10 min. The sections were thenwashed three times and incubated with a staining solution
(1 mg/ml 5-bromo-4-chloro-3-indolyl-b-D-galactopyranoside (X-
gal), 0.1% phosphate buffer, pH 7.5, 5 mM potassium ferrocyanide,
5 mM potassium ferricyanide, 0.02% NP-40, 0.01% sodium deoxy-
cholate, and 2 mM MgCl2) for 4–5 h to visualize b-gal activity.
2.5. Bone histomorphometry
To assess the parameters for bone histomorphometry, 15-week-
old femalemice of caERa (n = 7) andWT (n = 9)were double labeled
with subcutaneous injectionsof 30 mg/kgof tetracyclinehydrochlo-
ride (Sigma, St. Louis,MO) at 4 days before sacriﬁce, and 16 mg/kg of
calcein (Dojindo, Kumamoto, Japan) at 2 days before sacriﬁce. Tibiae
were removed from each mouse, and ﬁxed with 70% ethanol. They
were trimmed to remove the muscle, stained with Villanueva bone
stain for 7 days, dehydrated in graded concentrations of ethanol,
and embedded in methyl-methacrylate (Wako Chemicals,
Kanagawa, Japan) without decalciﬁcation. Frontal plane sections
(5-lm-thick) of the proximal tibia were cut using aMicrotome (LIE-
CA, Germany). The cancellous bone was measured in the secondary
spongiosa located 500 lm from the epiphyseal growth plate and
160 lm from the endocortical surface. Bone histomorphometric
measurements of the tibia weremade using a semiautomatic image
analyzing system (System Supply, Nagano, Japan) and a ﬂuorescent
microscope (Optiphot; Nikon, Tokyo, Japan) set at amagniﬁcation of
400. Standard bone histomorphometrical nomenclatures, sym-
bols, and units were used as described in the report of the ASBMR
Histomorphometry Nomenclature Committee [22]. Bone mineral
density (BMD) of the femora was measured using a PIXImus instru-
ment (Lunar Corp.,Madison,WI). Statistical analysiswas done using
Student’s t-test.
2.6. Quantitative PCR and measurement of OPG protein level
Primary mouse osteoblastic cells were isolated from calvariae of
5-day-old neonates of caERaColI mice and wild type littermates as
described previously [23]. The cells were maintained in a-MEM
containing 10% FCS and antibiotics. Total RNA was extracted from
the cells at the third passage using the ISOGEN reagent (Nippon
Gene, Tokyo, Japan). To examine estrogen-regulated gene expres-
sion, primary osteoblastic cells prepared from wild type mice were
seeded in phenol-red free a-MEM containing 10% dextran-coated
charcoal-stripped FCS and infected with recombinant adenovirus
expressing caERa (Ad-caERa) or ﬂuorescent protein DsRed (Ad-
DsRed) at m.o.i. 10 for 24 h. The adenoviral vectors, Ad-caERa
and Ad-DsRed, were constructed using the Adenovirus Expression
Vector Kit (Takara, Tokyo, Japan) following the manufacturer’s pro-
tocol. The cells were treated with 10 nM 17b-estradiol (E2), 1 lM
ICI182,780 (ICI) or vehicle for 24 h and then total RNA was isolated.
Quantitative real-time RT-PCR (qPCR) analysis was performed as
described previously [24]. The sequences of PCR primers were as
follows: OPG, 50-GCCTGGGACCAAAGTGAATG and 50-TCTTGTGA
GCTGTGTCTCCGTTT; RANKL, 50-TGTCGTTAAAACCAGCATCAAAAT
and 50-TTTCGTGCTCCCTCCTTTCA; IL-6, 50-TCCTACCCCAATTTC-
CAATGC and 50-GTCCTTAGCCACTCCTTCTGTGA; and ERa, 50-ACA-
GACACTTTGATCCACCTGATG and 50-AGATGCTCCATGCCTTTGTTA
CTA. The primers for ERa were designed in common sequences
of human and mouse ERa. To assess the caERa transgene expres-
sion, primers; 50-ATGGACTACAAGGACGATGATGAC-30 and 50-
GCAGTAGGGCCATCCCAGAT-30 corresponding to Flag and human
ERa sequences, respectively, were used. The comparison of PCR
product amounts was carried out by the comparative cycle thresh-
old (CT) method, using Gapdh as a control. The amount of OPG re-
leased into the culture medium was determined using a mouse
OPG/TNFRSF11B Immunoassay kit (R&D Systems, Minneapolis,
MN) according to the manufacturer’s instructions. Values were
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a protein-containing fraction of the RNA isolation procedure. The
experiments were independently repeated at least three times,
each performed in triplicate. Results were shown as mean ± S.D.
Statistical analysis was performed using Student’s t-test.
2.7. Osteoclast formation assay
Wild type mouse bone marrow cells from long bones were cul-
tured in a-MEM containing 10% FCS and 5 ng/ml M-CSF (Pepro-
Tech, Rocky Hill, NJ) for 16 h. Non-adherent cells were harvested
and cultured for three more days in the presence of 30 ng/ml M-
CSF. Floating cells were removed and adherent cells were used as
osteoclast precursors. The cells were further cultured in medium
supplemented with 30 ng/ml M-CSF and 50 ng/ml RANKL (Pepro-
Tech) for 7 days. Equal volume of conditioned medium prepared
by caERaColI primary osteoblasts were added to the medium. The
culture plate was stained for TRAP-positive multinuclear cells
(TRAP + MNCs) using the leukocyte acid phosphatase (TRAP) kit
(Sigma–Aldrich). TRAP + MNCs containing more than three nuclei
were counted.
3. Results
3.1. Generation of caERa
To assess the function of ERa in vivo, we generated a constitu-
tively active mutant of human ERa with a Y537S substitution
(Fig. 1A). Studies have demonstrated that this tyrosine 537 is an
important phosphorylation site with potential roles in regulating
ERa ligand binding, homodimerization, and transactivation [25].
A luciferase assay using estrogen-responsive element (ERE)-driven
reporter plasmids showed that caERa enhances ERE-driven tran-
scription regardless of estrogen (Fig. 1B). The caERa transcription
activity could be suppressed by the anti-estrogen ICI182,780
(Fig. 1B). The transcriptional activity of caERa was the same level
to wild type ERa (Fig. 1C). We utilized this caERamutant to exam-
ine the in vivo gain-of-function effects of ERa.A
B C
Fig. 1. Construction of constitutively active ERa (caERa). (A) Schematic represen-
tation of caERa that has a substitution of tyrosine to serine at position 537. The
caERa-expressing plasmid was generated by mutagenesis using Flag-tagged ERa
cDNA. (B) Transcription activity of caERa. HeLa cells were transfected with the
estrogen responsive element-driven luciferase reporter (ERE-tk-Luc), the luciferase
reporter for internal control (pRL-CMV), and the expression plasmid for caERa in
phenol red-free DMEM containing 10% dccFCS. After transfection, the cells were
treated with or without 10 nM 17b-estradiol (E2) or 1 lM ICI182,780 (ICI) for 24 h,
and then luciferase assays were performed. (C) Transcription activity of ERa.
Luciferase assay was performed using an expression vector for wild type ERa
instead of caERa. Data were represented as the mean ± S.D. of three independent
experiments. Statistical analysis was performed using Student’s t-test, ⁄⁄P < 0.01.3.2. Generation of conditional transgenic mice that express caERa in
osteoblasts
To investigate the in vivo effects of ERa overexpression, we em-
ployed a conditional transgenic mouse system to express the caERa
transgene (Fig. 2A). We ﬁrst established a ﬂoxed GFP-caERa trans-
genic mouse line bearing the CAG-GFPﬂoxed-caERa transgene. The
CAGpromoter has the potential for ubiquitous expression in various
tissues.We expected thatmice bearing this constructwould express
GFP but not caERa due to the poly(A) signal sequence that is located
immediately after the GFP sequence. In the presence of Cre recombi-
nase, the GFP sequence would be deleted and caERa would be ex-
pressed instead of GFP under CAG promoter control. The CAG-
GFPﬂoxed-caERa constructwas introduced intopronuclear stage eggs
of C57BL/6 bymicroinjection, andwe obtained CAG-GFPﬂoxed-caERa
transgenic mice. Genomic polymerase chain reaction (PCR) using
GFP-speciﬁc primers was used to verify the transgene integration
(Fig. 2B). Fluorescent stereomicroscopic analysis of the tail
(Fig. 2C) from the transgenic mice conﬁrmed expression of the GFP
protein.
We utilized ColI-Cre mice [18] to achieve conditional caERa
expression in osteoblasts. In order to inspect Cre expression in
osteoblasts, we generated mice heterozygous for the ColI-Cre and
ROSA26LacZ transgenes by breeding a homozygous ROSA26LacZ
mice with homozygous ColI-Cre mice. Embryos and spines were
prepared from heterozygous neonates at 10 dpc and P1, respec-
tively, and monitored by X-gal staining (Fig. 2D and E). As shown
in the ﬁgure, LacZ-positive signals were detected in osteoblasts
in these tissues. The osteoblast-speciﬁc expression of Cre recombi-
nase to induce recombination in this ColI-Cre mouse has been
previously demonstrated by Karsenty and co-workers [18]. Next,
we generated the conditional transgenic mice caERaColI that
express the caERa protein in osteoblasts.
3.3. Increased BMD of mice expressing caERa in osteoblasts
Dual energy X-ray absorptiometry was used to measure the
femoral BMD of caERaColI female transgenic mice compared with
WT controls. Fig. 3A shows an increase in femoral BMD observed
in the caERaColI compared with WT controls. The effects of caERa
on bone remodeling were further analyzed by histomorphometry
at the proximal tibia. As shown in Fig. 3B, caERaColI mice displayed
increased osteoid formation within the marrow cavity. Fig. 3C indi-
cated that the marks produced by calcein and tetracycline
appeared to be similar in width. The caERaColI mice signiﬁcantly
increases bone mass – bone volume per tissue volume (BV/TV)
(Fig. 3D). As shown in Fig. 3H, a histological index of bone resorp-
tion, the osteoclast number per bone surface (N.Oc/BS) was signif-
icantly decreased in caERaColI mice compared with WT mice.
Additional histological indices of bone resorption, both the bone
surface covered by osteoclasts (Oc.S/BS) and the eroded surface
(ES/BS), tended to decrease (Fig. 3F and G). Unexpectedly, the
caERaColI mice revealed no difference in mineral apposition rate
(MAR) (Fig. 3E). These data suggest that caERa overproduction in
osteoblasts decelerates bone resorption and elevates bone mass.
3.4. OPG mRNA and protein are upregulated in caERa-expressing
osteoblasts
To further examine themechanism of increase in BMD in caERa-
ColI mice, expression levels of OPG, RANKL and IL-6 mRNA were
quantiﬁed in primary osteoblasts prepared from calvaria. Transgene
expressionwas conﬁrmed in the primary osteoblasts prepared from
caERaColImice (Fig. 4A). Total ERa expression levels ofmouse endog-
enous ERa and the transgene caERa were examined using primers




Fig. 2. Generation of conditional transgenic mice expressing caERa in osteoblasts. (A) Schematic representation of CAG-GFPFloxed-caERa transgene. The construct expresses
GFP but not caERa since the loxP-ﬂanked GFP gene has a stop codon at the end of the gene. In the presence of Cre recombinase, the GFP sequence would be excised and caERa
would be expressed instead of GFP under CAG promoter control. (B) Genotyping of caERa transgenic mice. Transgenic mice were identiﬁed by PCR assays of genomic DNA
extracted from the tail using primers derived from the 50- and 30-ﬂanking sequences of GFP. A positive signal was detected as a 1.9-kb product. (C) Stereomicroscopic image of
tail from CAG-GFPFloxed-caERa transgenic mouse. GFP ﬂuorescence (green) was visualized by stereomicroscopy. (D and E) A ColI-Cre transgenic mouse was mated with a
ROSA26LacZ tester mouse, and the resulting embryos (10 dpc) and spines from ColI-Cre+; ROSA26LacZ+ newborn mice (P1) were stained with X-gal.
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blasts expressERamRNAbymore than4-fold compared towild type
primary osteoblasts. As shown in Fig. 4B, OPG mRNA was signiﬁ-
cantly upregulated in primary osteoblasts from caERaColI mice. In
addition, IL-6 mRNA was downregulated in caERaColI primary oste-
oblasts, but RANKLmRNAwas not (Fig. 4D andE). OPGprotein levels
were obviously higher in culture media from primary osteoblasts
derived from caERaColI mice compared to those from WT mice
(Fig. 4F). These results suggest that estrogen receptors stimulate
OPG expression in osteoblasts, whereas they inhibit IL-6 expression.
To examine the effect of estrogen on these osteoclast-associated
gene expressions, primary osteoblasts derived from wild type mice
were infected with or without recombinant adenovirus expressing
the caERa or DsRed for control, and treated with E2 or ICI. The
overexpression of caERa was conﬁrmed in the Ad-caERa infected
primary osteoblasts (Fig. 4G). As shown in Fig. 4H, qPCR assay
showed that OPG mRNA was upregulated by either E2 treatment
or Ad-caERa infection. The expression levels of RANKL mRNA were
not changed by these treatments; however, IL-6 mRNA was down-
regulated by either E2 treatment or Ad-caERa infection (Fig. 4I andJ). Moreover, ICI inhibited the estrogen-mediated increase of OPG
mRNA and reversed E2-dependent repression of IL-6 mRNA. These
data indicated that the caERa signaling mimics the endogenous
ERa signaling in wild-type osteoblasts, and the differential gene
expression of OPG and IL-6 in caERa-expressing osteoblasts will
contribute to the alteration of bone tissue with reduced bone
resorption and high BMD in caERa transgenic mice.
Next, we examined whether osteoclast differentiation is im-
paired in the presence of medium conditioned by caERaColI pri-
mary osteoblasts. In support of our ﬁndings, the number of
TRAP-positive multinuclear cells were decreased in the medium
conditioned by caERaColI primary osteoblasts compared to that of
wild-type primary osteoblasts (Fig. 4K and L).
4. Discussion
In the present study, we generated conditional transgenic mice
using a Cre/loxP system to explore the in vivo function of human
ERa in osteoblasts by using the caERa mutant. CAG-GFPFloxed-
caERa transgenic mice expressing GFP but not caERa were gener-
A B
C
D E F G H
Fig. 3. Increased bone mineral density (BMD) of caERaColI mice. (A) BMD of 15-week-old female mice from caERaColI (n = 7) and WT (n = 9) were measured using dual energy
X-ray absorptiometry (DEXA). Values are represented as mean ± S.D. ⁄Signiﬁcantly different versus control at P < 0.05. (B) Bone histomorphometric analysis was performed as
described in Section 2. Panels are representative sections stained with Villanueva bone stain. (C) Fluorescence microscopy of bone sections derived from the caERaColI and WT
mice. The widths between the labeling lines of calcein and tetracycline are indicated. (D–H) Bone turnover parameters as measured by dynamic bone histomorphometry after
calcein and tetracycline labeling. Parameters are measured in the proximal tibia of 15-week-old caERaColI (n = 7) and WT (n = 9) female mice. BV/TV: bone volume per tissue
volume; MAR: mineral apposition rate; ES/BS: eroded surface per bone surface; Oc.S/BS: osteoclast surface per bone surface; N.Oc/BS: osteoclast number per bone surface.
Values are represented as mean ± S.D. Statistical analysis was performed using Student’s t-test, ⁄P < 0.05; ⁄⁄P < 0.01.
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osteoblasts. The caERaColI mice had higher BMD compared with the
WT mice. Histomorphometric analysis revealed that the number of
osteoclasts was signiﬁcantly decreased in caERaColI mice. Further-
more, primary osteoblasts from caERaColI mice expressed higher
levels of OPG mRNA and protein and lower levels of IL-6 mRNA.
Therefore, these results suggested that ERa plays a critical role in
gene expression associated with osteoclast differentiation in oste-
oblasts and affects bone resorption by osteoclasts.
OPG is a naturally occurring soluble member of the TNF recep-
tor superfamily that binds to RANKL [26]. OPG acts as a secreted
decoy receptor to neutralize RANKL and negatively regulate osteo-
clast differentiation, activity, and survival [8]. The ratio of RANKL
to OPG is assumed to be a critical determinant for osteoclast devel-
opment and bone resorption. OPG prevents bone loss when admin-
istered to ovariectomized rats [8], induces osteoporosis when
ablated in knockout (KO) mice [27,28], and induces osteopetrosis
when overexpressed in transgenic mice [8]. 17b-Estradiol also
dose-dependently increases OPG mRNA and protein levels in cul-
tured osteoblastic cells [10]. Our data strongly support that osteo-
blastic ERa mediates OPG secretion.
Estrogen also modulates the production of bone-resorbing cyto-
kines such as interleukin (IL)-1, IL-6, tumor necrosis factor (TNF)-a,macrophage colony-stimulating factor (M-CSF), prostaglandins,
and transforming growth factor-b by osteoblasts or osteoclasts
[29]. We demonstrated in this study that primary osteoblasts pre-
pared from caERaColI had decreased levels of IL-6 mRNA that is
known to be produced by osteoblasts and induces bone resorption.
It is also possible that ERa in osteoblasts can affect cytokine pro-
duction by osteoblasts, affecting on osteoclasts.
The caERaColI mice showed no change of MAR in bone histomor-
phometric analysis, therefore, it is speculated that differentiation
of osteoblasts expressing caERa is not affected in vivo. However,
some reports showed that ERa and estrogen promote osteoblast
differentiation [30,31]. Our results do not rule out this possibility
because differentiation of caERaColI osteoblasts is not investigated.
In addition, we speculate that the female caERaColI mice would re-
sist to bone loss induced by ovariectomy. The caERaColI mice will
be also useful to study the ERa function in male. These points will
be addressed by future studies.
Gene KO mice disrupting ERa and ERb were utilized to analyze
ER function in bone tissues [32,33]. However, bone loss and high
bone turnover were not markedly observed in these KO mice
[1,33]. This unexpected maintenance of bone mass is considered
to be caused by increased circulating estradiol and testosterone
levels because ER inactivation impairs the negative feedback sys-




Fig. 4. Increased osteoprotegerin (OPG) expression in primary osteoblasts derived from caERaColI mice. Primary mouse osteoblasts were isolated from calvariae of 5-day-old
neonates of caERaColI mice and their wild-type littermates. Total RNA was extracted from the cells and subjected to quantitative real-time RT-PCR (qPCR) analysis with the
primers for amplifying caERa transgene (A), both mouse endogenous ERa and caERa transgene (B), OPG (C), RANKL (D) and IL-6 (E). Comparison of the PCR product amounts
was carried out using the comparative cycle threshold (CT) method using GAPDH as a control. (F) The amount of OPG in the culture media of primary osteoblasts was
determined using a mouse OPG immunoassay kit. Values were normalized with the amount of total protein. (G–J) Estrogen regulation of OPG, RANKL and IL-6 mRNA in
primary osteoblasts. Primary osteoblasts isolated from wild-type mouse were infected with or without recombinant adenovirus expressing the caERa or DsRed (control).
After 24 h, the cells were treated with 10 nM 17b-estradiol (E2), 1 lM ICI182,780 (ICI) or vehicle for 24 h, and then qPCR was performed using the primers for amplifying both
mouse endogenous ERa and caERa transgene (G), OPG mRNA (H), RANKL mRNA (I) and IL-6 mRNA (J). (K and L) Conditioned medium prepared from caERa primary
osteoblasts inhibits osteoclast differentiation. Bone marrow cells were cultured in the presence of conditioned medium prepared from caERa and wild-type primary
osteoblasts for 7 days and then subjected to TRAP staining (original magniﬁcation, 200) (L). TRAP-positive multinuclear cells containing more than three nuclei were
counted (K). The experiments were independently repeated at least three times, each performed in triplicate. Results were shown as mean ± S.D. Statistical analysis was
performed using Student’s t-test, ⁄P < 0.05; ⁄⁄P < 0.01.
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Nakamura et al. generated osteoclast-speciﬁc ERa KO mice and
found that the mutant females exhibited trabecular bone loss, a
ﬁnding similar to the osteoporotic bone phenotype in postmeno-
pausal women [34]. The osteoclast-speciﬁc ERa KO mice did dem-
onstrate that ERa is required for the induction of Fas ligand (FasL)
expression and estrogen-mediated apoptosis in osteoclasts. These
observations provide an explanation for the osteoprotective func-
tion of estrogen [34]. Transgenic mouse models were also gener-
ated to investigate the effects of ERa overexpression, although
they were designated or utilized to investigate ERa function in
reproductive organs of female mice [35,36]. In the present study,
we generated a conditional transgenic mouse model that revealed
an in vivo role of ERa in osteoblasts. This gene-engineered animal
model will be a powerful tool for understanding cell-speciﬁc and
tissue-speciﬁc ERa functions in vivo.
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